-
Graves病是一种常见的内分泌疾病。由于患者血中可检查到多种自身抗体, 因而被认为是一种自身免疫性疾病。什么原因导致机体对甲状腺组织抗原的耐受状态被打破?其机制迄今仍未完全阐明。自1995年Sakaguchi等[1]首次报道小鼠外周循环中CD4+CD25+ T细胞具有抑制多器官自身免疫性疾病功能以来, 该群细胞受到了广泛关注, 为了与传统免疫理论中的抑制性T细胞相区别, 此类细胞被命名为“CD4+CD25+调节性T细胞(regulatory T cells, Treg)”。通常认为其在CD4+ T细胞中所占比例下降, 与多种自身免疫性疾病关系密切。但国内为数不多的有关CD4+CD25+Treg与Graves病关系的研究结果却并未显示出Graves病患者外周血中CD4+CD25+Treg的明显减少[2-3]。研究显示, 人类外周循环中也存在5%~10%的CD4+CD25+Treg, 但人CD25的表达情况明显不同于小鼠:小鼠CD4+T细胞表面CD25的数量比较均匀一致, CD4+CD25+与CD4+CD25-T细胞分界清晰, 呈相互独立的单一细胞群; 而人CD4+CD25+T细胞表面CD25的表达量根据荧光强度可分为弱、中、强3个等级, 目前认为仅CD25强阳性的CD4+T细胞(CD4+CD25high)能特异性代表人CD4+CD25+Treg[3]。为进一步了解Treg与Graves病的关系, 本研究以CD4+CD25+CD127-作为识别Treg的标志物, 对90例Graves病患者外周血中高表达CD25、同时低表达CD127的CD4+ Treg(CD4+CD25+CD127-Treg)进行检测, 以探讨Graves病中Treg的变化。
-
Graves病组外周血中TT3、TT4、FT3、FT4、TGAb、TMAb水平均高于正常对照组, 外周血中CD4+CD25+CD127-Treg数量较正常对照组明显降低[(1.39%±1.09%)vs.(4.59%±1.14%)], 差异有统计学意义(t=16.4, P<0.01) (表 1)。
组别 例数 年龄 CD4+CD25+CD127- Treg数量(%) TT3 (nmol/L) TT4 (nmol/L) FT3 (pmol/L) FT4 (pmol/L) TGAb (%) TMAb (%) 正常对照组 90 32.78±6.46 4.59±1.14 1.62±0.25 99.55±19.83 4.56±1.66 14.30±2.22 6.61±3.16 4.47±2.69 Graves病组 50 35.47±10.22 1.39±1.09 8.02±2.75 286.25±70.85 26.92±1.70 67.04±21.26 28.18±2.69 19.5±2.46 t值 1.90 16.4 21.10 22.59 11.87 22.71 7.74 8.63 p值 >0.05 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 注:表中,Treg:调节性T细胞;TT3:总三碘甲状腺原氨酸;TT4:总甲状腺素;FT3:游离三碘甲状腺原氨酸;FT4:游离甲状腺素;TGAb:甲状腺球蛋白抗体;TMAb:甲状腺微粒体抗体。 表 1 Graves病组与正常对照组CD4+CD25+CD127- Treg数量及甲状腺功能检测结果比较(x±s)
-
Graves病组CD4+CD25+CD127- Treg数量与TRAb水平呈负相关(r=-0.24, P<0.05), 与TT3、TT4、FT3、FT4、TGAB、TMAB水平呈负相关(r=-0.62、-0.65、-0.56、-0.71、-0.50、-0.15, P均<0.01), 与年龄无相关性(r=-0.15, P>0.05)。
CD4+CD25+CD127-调节性T细胞在Graves病中的变化及临床意义
Changes and clinical significance of CD4+CD25+CD127- regulatory T cells in Graves disease
-
摘要:
目的 通过观察Graves病患者外周血中CD4+CD25+CD127-调节性T细胞(Treg)数量的变化, 探讨Graves病发生的免疫学机制。 方法 采用流式细胞术检测90例Graves病患者和50名正常人外周血中CD4+CD25+CD127-Treg的比例, 同时测定甲状腺功能指标及甲状腺自身抗体水平。采用t检验进行组间比较, 采用线性相关分析法分析CD4+CD25+CD127- Treg与甲状腺功能指标的关系。 结果 90例Graves病患者与50名正常人外周血中CD4+CD25+CD127-Treg的比例分别为1.39%±1.09%和4.59%±1.14%, 两者间差异有统计学意义(t=16.4, P<0.01)。CD4+CD25+CD127- Treg数量与促甲状腺激素受体抗体水平呈负相关(r=-0.24, P<0.05), 与总三碘甲状腺原氨酸、总甲状腺素、游离三碘甲状腺原氨酸、游离甲状腺素、甲状腺球蛋白抗体、甲状腺微粒体抗体水平呈负相关(r=-0.62、-0.65、-0.56、-0.71、-0.50、-0.15, P均<0.01)。 结论 Graves病患者CD4+CD25+CD127-Treg数量减少, 且CD4+CD25+CD127- Treg数量与甲状腺功能指标及甲状腺自身抗体水平关系密切, 提示CD4+CD25+CD127-Treg数量减少可能与Graves病的发病有关。CD4+CD25+CD127-可能是人CD4+ T细胞中Treg的特异性标志物。 -
关键词:
- 格雷夫斯病 /
- T淋巴细胞, 调节性 /
- 抗原, CD4 /
- 抗原, CD25 /
- 抗原, CD127
Abstract:Objective To investigate the mechanism of Graves disease by observing the changes of CD4+CD25+CD127- regulatory T cells (Treg) population in the patients. Methods Flow cytometry was used to detect the proportion of CD4+CD25+CD127- Treg of CD4+ T cells in 90 Graves disease patients (Graves disease group) and 50 healthy adults(control group). Thyroid function and autoantibody levels were determined simultaneously. The t test was adopted for comparison between groups. The relationship between CD4+CD25+CD127- Treg and thyroid function was analyzed by linear correlation analysis. Results The percentages of CD4+CD25+CD127-Treg in Graves disease group and control group were 1.39%±1.09% and 4.59%±1.14% separately. There was significant difference between the two groups(t=16.4, P < 0.01). There were negative correlation between CD4+CD25+CD127- Treg percentages and total triiodothyronine, total thyroxine, free triiodothyronine, free thyroxine and thyrotropin receptor antibody, thyroglobulin antibody, thyroid microsomal antibody(r=-0.62, -0.65, -0.56, -0.71, -0.50, -0.15, all P < 0.01). Conclusions The reduction of CD4+CD25+CD127-Treg percentages in Graves disease group and close relations of CD4+CD25+CD127-Treg with thyroid function and thyroid autoantibody levels suggest that CD4+CD25+CD127-Treg decrease in the number may be associated with the onset of Graves disease. CD4+CD25+CD127- may be the specific marker of Treg. -
Key words:
- Graves disease /
- T-lymphocytes, regulatory /
- Antigens, CD4 /
- Antigens, CD25 /
- Antigens, CD127
-
表 1 Graves病组与正常对照组CD4+CD25+CD127- Treg数量及甲状腺功能检测结果比较(x±s)
组别 例数 年龄 CD4+CD25+CD127- Treg数量(%) TT3 (nmol/L) TT4 (nmol/L) FT3 (pmol/L) FT4 (pmol/L) TGAb (%) TMAb (%) 正常对照组 90 32.78±6.46 4.59±1.14 1.62±0.25 99.55±19.83 4.56±1.66 14.30±2.22 6.61±3.16 4.47±2.69 Graves病组 50 35.47±10.22 1.39±1.09 8.02±2.75 286.25±70.85 26.92±1.70 67.04±21.26 28.18±2.69 19.5±2.46 t值 1.90 16.4 21.10 22.59 11.87 22.71 7.74 8.63 p值 >0.05 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 注:表中,Treg:调节性T细胞;TT3:总三碘甲状腺原氨酸;TT4:总甲状腺素;FT3:游离三碘甲状腺原氨酸;FT4:游离甲状腺素;TGAb:甲状腺球蛋白抗体;TMAb:甲状腺微粒体抗体。 -
[1] Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL2-receptor alpha-chains(CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 1995, 155(3): 1151-1164. [2] 李惠芝, 冯波, 华咏, 等. Graves病CD4+CD25+T调节细胞水平的变化.同济大学学报:医学版, 2009, 30(5): 54-56.
[3] 高书涛, 朱铁年, 张玉娜, 等. CD4+CD25+调节性T细胞在自身免疫性甲状腺疾病中数量和功能变化.中国免疫学杂志, 2011, 27(3): 269-273.
[4] 陆再英, 钟南山.内科学. 7版.北京:人民卫生出版社, 2008:712-721.
[5] Shevach EM. CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol, 2002, 2(6): 389-400. doi: 10.1038/nri821 [6] Ramsdell F, Ziegler SF. Transcription factors in autoimmunity. Curr Opin Immunol, 2003, 15(6): 718-724. doi: 10.1016/j.coi.2003.09.008 [7] Baecher-Allan C, Viglietta V, Hafler DA. Human CD4+CD25+ regulatory T cells. Semin Immunol, 2004, 16(2): 89-98. [8] Saitoh O, Nagayama Y. Regulation of Graves′ hyperthyroidism with naturally occurring CD4+CD25+ regulatory T cells in a mouse model. Endocrinology, 2006, 147(5): 2417-2422. doi: 10.1210/en.2005-1024 [9] 党珊, 施秉银. Graves病患者CD4+CD25+调节性T细胞的变化.中华内分泌代谢杂志, 2007, 23(3):253-254. doi: 10.3760/j.issn:1000-6699.2007.03.019
[10] Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin(IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cell. J Exp Med, 2006, 203(7): 1693-1700. doi: 10.1084/jem.20060468 [11] 王会平, 翟志敏, 张爱梅, 等. CD4+CD25+CD127low识别人外周血CD4+CD25+调节性T细胞的优势.中国免疫学杂志, 2008, 24(12):1059-1062.